2nd Quarter - Report

NOSSAMAN LLP for AMERISOURCEBERGEN CORPORATION (FORMERLY "AMERISOURCEBERGEN SPECIALTY GROUP")

Firm
Client
Income
$30,000
Expenses
—

What was lobbied

3 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

(H.R.800/S. 806) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. ASP Generally (in the context of deficit reduction). Sequestation cuts to cancer care

LobbyistCovered position, as disclosed
SHELBY LYNNE HAGENAUER —
BRENT HEBERLEE —
TIMOTHY W JENKINS —
SHERRY HARPER WIDICUS —

Contacted: SENATE; HOUSE OF REPRESENTATIVES

Bills named: H.R. 800 (113th), S. 806 (113th)

Taxation/Internal Revenue Code TAX

Repeal of LIFO (Last in, First Out).

LobbyistCovered position, as disclosed
SHELBY LYNNE HAGENAUER —
BRENT HEBERLEE —
TIMOTHY W JENKINS —
SHERRY HARPER WIDICUS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Pharmacy PHA

(H.R.800) legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Pharmaceutical pedigree anti-counterfeiting legislation (H.R.1919/S.957). Legislation pertaining to drug manufacturing shortages.

LobbyistCovered position, as disclosed
SHELBY LYNNE HAGENAUER —
BRENT HEBERLEE —
TIMOTHY W JENKINS —
SHERRY HARPER WIDICUS —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 1919 (113th), H.R. 800 (113th), S. 957 (113th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.